Inhaled corticosteroids (ICS) have proven to be the most effective and essential therapy for the treatment of bronchial asthma. The 2007 National Asthma Education and Prevention Program guidelines recommend ICS as preferred therapy for patients with mild to severe persistent asthma. Mometasone furoate (MF) is a relatively new ICS agent with high affi nity for the glucocorticoid receptor. It is …
Several randomized, double-blind, placebo-controlled clinical trials have demonstrated the efficacy of mometasone furoate nasal spray (MFNS) in the treatment of allergic rhinitis (AR) thus allowing for a meta-analysis to determine the overall treatment effect
Current treatment guidelines recommend intranasal corticosteroids or nonsedating antihistamines as first-line therapy for allergic rhinitis (AR). Because of concerns regarding the systemic safety of intranasal corticosteroids in children, the present study was conducted to evaluate systemic activity of mometasone furoate nasal spray (MFNS) in children as young as 2 years of age with AR. This wa…
Once-daily mometasone furoate nasal spray (MFNS) is a new intranasal glucocorticoid for the treatment of seasonal allergic rhinitis and perennial rhinitis, and for the prophylaxis of seasonal allergic rhinitis. This paper reviews key findings from the clinical development program for MFNS, comprising more than 20 clinical trials with more than 6000 patients worldwide
Allergic rhinitis is the most prevalent of allergic diseases in the world. Nasal corticosteroids are the most applicable drugs for the treatment of allergic rhinitis. In this study, we compared the efficacy of fluticasone propionate (FP) and mometasone furoate (MF) nasal sprays in the treatment of allergic rhinitis based on total nasal symptom score (TNSS) questionnaire.